Baxalta seeks UK MHRA approval for BAX 826 trial of to treat hemophilia A

US-based biopharmaceutical firm Baxalta has submitted a clinical trial application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) seeking approval to start a first-in-human clinical trial of BAX 826, an investigational, ex…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news